LTI-03 was shown to reduce inflammation and scarring in lung tissue collected from IPF patients and analyzed in a lab, ...
For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.
Diabetes mellitus (DM) is a possible risk factor for post-COVID-19 pulmonary fibrosis (PCPF), according to meta-analysis study findings published in BMC Pulmonary Medicine.
Idiopathic pulmonary fibrosis is a potentially fatal disease currently without treatment, in which lung tissue develops scarring and becomes stiff, making breathing increasingly difficult over time.
A research group from the National Cancer Research Center (CNIO) has found that an alteration in the POT1 gene prevents lung tissue from regenerating, which over time makes breathing difficult. The ...
Topline data were announced from a phase 3 trial evaluating efzofitimod in patients with pulmonary sarcoidosis.
A new research paper was published in Volume 17, Issue 8 of Aging-US on August 8, 2025, titled "AI-driven toolset for IPF and ...
Polyethylene terephthalate microplastics are the most common microplastics encountered in daily life, and there are several reasons why they may play a role in lung diseases like idiopathic pulmonary ...
The readout validates SpliSense' platform, supporting advancement of the Company's additional pulmonary programs, for muco-obstructive diseases and idiopathic pulmonary fibrosis, into the clinic in ...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the ...
The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical ...
CAL101 is a first-in-class monoclonal antibody targeting S100A4, a damage-associated molecular pattern (DAMP) protein associated with serious and life-threatening fibrotic disorders Phase 2 AURORA ...